alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<PAGE>
 
                                                                    EXHIBIT 24.6
STATE OF MASSACHUSETTS

COUNTY OF PLYMOUTH

                               POWER OF ATTORNEY
                               -----------------

     KNOW ALL MEN BY THESE PRESENTS, that I, Warren C. Smith, Jr., a Director of
JUST FOR FEET, INC., a Delaware corporation (the "Company"), do constitute and
appoint Harold Ruttenberg and Eric L. Tyra, and each of them, my true and lawful
attorneys-in-fact and agents, each with full power of substitution and
resubstitution, for me in any and all capacities, to sign, on my behalf and in
my stead pursuant to the requirements of the Securities Act of 1933, as amended
and the Securities Exchange Act of 1934, as amended (i) a Registration Statement
on Form S-8 to register additional shares for issuance pursuant to the Just For
Feet, Inc. 1997 Employee Incentive Plan; (ii) post-effective amendments to the
following Registration Statements: 33-80578, 33-96588, 333-06531, 333-28041,
333-96584, 333-26345 and 333-28039; and (iii) the Company's Annual Report on
Form 10-K for the fiscal year ended January 30, 1999, and to file the same with
the Securities and Exchange Commission, together with all exhibits thereto and
other documents in connection therewith, and to sign on my behalf and in my
stead, in any and all capacities, any amendments to said Registration Statements
or Reports, incorporating such changes as the said attorneys-in-fact deem
appropriate, hereby ratifying and confirming all that said attorneys-in-fact, or
their substitute or substitutes, may do or cause to be done by virtue hereof.

     IN WITNESS WHEREOF, I have hereunto set my hand and seal this 4th day of
March, 1999.


                                     /s/ Warren C. Smith, Jr.
                                    -------------------------------
                                    Warren C. Smith, Jr.


                                ACKNOWLEDGEMENT
                                ---------------

     BEFORE me this 4th day of March, 1999, came Warren C. Smith, Jr.,
personally known to me, who in my presence did sign and seal the above and
foregoing Power of Attorney and acknowledged the same as his true act and deed.


                                     /s/ Eileen M. Messlinger
                                    -------------------------------
                                    NOTARY PUBLIC

                                    State of Massachusetts

                                    My Commission Expires:

                                          1/15/03
                                    -------------------------------
Exhibit 32.2



CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Quarterly Report on Form 10-Q of Trimeris, Inc. (the Company) for the quarterly period ending September 30, 2005
as filed with Securities and Exchange Commission on the date hereof (the Report), I, Robert R. Bonczek, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the
Sarbanes-Oxley Act of 2002, that to my knowledge:



(1) The
Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and



(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



|                       
|-----------------------
|/s/ ROBERT R. BONCZEK  
|Robert R. Bonczek      
|Chief Financial Officer



November 8, 2005



The foregoing certification is
being furnished solely pursuant to 18 U.S.C. § 1350 and is not being filed as part of the Report or as a separate disclosure document.



A signed original of this written statement required by § 906 has been provided to Trimeris, Inc. and will be retained by Trimeris, Inc. and
furnished to the Securities and Exchange Commission or its staff upon request.
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
FINANCIAL STATEMENTS OF RACI HOLDING, INC. FOR THE YEAR-TO-DATE ENDED DECEMBER
31, 1999 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL
STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               DEC-31-1999
<CASH>                                          26,300
<SECURITIES>                                         0
<RECEIVABLES>                                   59,100
<ALLOWANCES>                                     2,500
<INVENTORY>                                     70,800
<CURRENT-ASSETS>                               181,200
<PP&E>                                         153,700
<DEPRECIATION>                                  65,900
<TOTAL-ASSETS>                                 358,800
<CURRENT-LIABILITIES>                           90,100
<BONDS>                                         86,700
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                     127,200
<TOTAL-LIABILITY-AND-EQUITY>                   358,800
<SALES>                                        399,400
<TOTAL-REVENUES>                               399,400
<CGS>                                          271,100
<TOTAL-COSTS>                                  271,100
<OTHER-EXPENSES>                                76,500
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              14,100
<INCOME-PRETAX>                                 37,700
<INCOME-TAX>                                    14,700
<INCOME-CONTINUING>                             23,000
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    23,000
<EPS-BASIC>                                      29.68
<EPS-DILUTED>                                    28.89


</TABLE>
Third Amendment to LTIP



 EXHIBIT 10(q-4) 

THIRD AMENDMENT 
 TO THE 
 LONG TERM INCENTIVE PLAN 

OF EMCOR GROUP, INC. 
 This Third Amendment to the EMCOR Group, Inc. Long Term Incentive Plan is made as of March 23, 2012. 
 NOW, THEREFORE, the Long Term Incentive Plan is hereby amended as follows: 
 1. Section 2 is hereby amended to add the following paragraph to the definition of Earnings Per Share: 
 “Earnings Per Share” for a Three Year Applicable Period commencing on or after January 1, 2012 shall mean the aggregate of the diluted earnings per share of the Company’s Common Stock
for each of such three years, as reported in the Company’s “Consolidated Statements of Operations” for such years in accordance with generally accepted accounting principles; provided, however, that in computing net income to arrive
at any such year’s earnings per share there shall be excluded from the calculation of such net income (a) non-cash charges associated with the write-down of balance sheet values of assets, (b) investment banking, consulting, legal,
and accounting fees and related disbursements directly associated with any proposed or consummated (i) acquisition or investment or (ii) sale or disposition of Company assets or securities, (c) the effect of any changes in statutory
tax rates from those in effect on March 29, 2010, (d) restructuring charges due to sale or closure of a subsidiary’s business, (e) the cumulative effect of any change in accounting principles, and (f) charges associated with
withdrawal liabilities relating to multi-employer pension plans and lump sum type surcharges (as opposed to increases in hourly contribution rates) assessed by multi-employer pension plans, to ameliorate underfunding in their respective plans; and
provided further, however, that the Compensation Committee may, within the first 90 days of a Three Year Applicable Period, adjust any such period’s Earnings Per Share, to the extent permitted under Section 162(m) of the Code, to omit the
impact on such Earnings Per Share of extraordinary items, gains or losses on the acquisition or disposal of a business, and/or unusual or infrequently occurring events and transactions.” 

IN WITNESS WHEREOF, the undersigned has executed this Amendment as of the date first written above. 

 

			
	EMCOR GROUP, INC.
		
	 By:
	 	         /s/ Anthony J. Guzzi

		 	 President and Chief Executive Officer
----

|   | /s/ Selwyn Joffe        |   |
|--------|-------------------------|--------|
|   | Selwyn Joffe            |   |
|   | Chief Executive Officer |   |
|   | July 31, 2017           |   |

|   | /s/ David Lee           |   |
|--------|-------------------------|--------|
|   | David Lee               |   |
|   | Chief Financial Officer |   |
|   | July 31, 2017           |   |

|   | /s/ Kevin Daly           |   |
|--------|--------------------------|--------|
|   | Kevin Daly               |   |
|   | Chief Accounting Officer |   |
|   | July 31, 2017            |   |

----
##### 



Exhibit 32.01 Written Statement of Chief Executive Officer
Pursuant to Section 906
of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350) The undersigned, the Chief Executive Officer of Guilford Pharmaceuticals Inc. (the Company),
hereby certifies that, to his knowledge on the date hereof:  (a)
    the Annual Report on Form 10-K of the Company for the year ended December 31, 2004 filed on
the date hereof with the Securities and Exchange Commission (the Report) fully complies with
the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and(b)
    information contained in the Report fairly presents, in all material respects, the financial
condition and results of operations of the Company. Date: March 4, 2005 /s/ Dean J. Mitchell
Order entered September 2 6 , 2022

In The 

### Court of Appeals Fifth District of Texas at Dallas

No. 05

- 22

- 00156

- CR

THOMAS LINZ JOHNSON , Appellant

V.

THE STATE OF TEXAS , Appellee

On Appeal from the 28 2nd Judicial District Court

Dallas County, Texas Trial Court Cause No. F 15

- 58525

- S

O RDER

Before the Court is the State ’s September 22, 2022 first motion to extend the

time to file the State ’ s brief. Although the State ’ s motion states it is unopposed and

contains a certificate of con ference, appellant has filed an objection to the proposed

extension. We GRANT the motion to the extent we ORDER the State ’ s brief filed
by November 8, 202 2

.

/s/ ROBERT D. BURNS, III CHIEF JUSTICE
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JUL-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                           2,244
<SECURITIES>                                     4,584
<RECEIVABLES>                                   30,195
<ALLOWANCES>                                     (800)
<INVENTORY>                                          0
<CURRENT-ASSETS>                                38,524
<PP&E>                                         434,463
<DEPRECIATION>                               (232,332)
<TOTAL-ASSETS>                                 271,062
<CURRENT-LIABILITIES>                           48,355
<BONDS>                                        263,579
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           122
<OTHER-SE>                                    (40,994)
<TOTAL-LIABILITY-AND-EQUITY>                   271,062
<SALES>                                         52,894
<TOTAL-REVENUES>                                52,894
<CGS>                                           21,434
<TOTAL-COSTS>                                   21,434
<OTHER-EXPENSES>                                28,637
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               6,990
<INCOME-PRETAX>                                (4,075)
<INCOME-TAX>                                        69
<INCOME-CONTINUING>                            (4,144)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (4,144)
<EPS-BASIC>                                     (0.34)
<EPS-DILUTED>                                   (0.34)


</TABLE>
EXHIBIT
32: Rule 13a-14(b) Certifications





The
undersigned officers certify that this report fully complies with the
requirements of Section 13(a) of the Securities Exchange Act of 1934, and that
the information contained in the report fairly presents, in all material
respects, the financial condition and results of operations of Jinzanghuang
Tibet Pharmaceuticals, Inc.





A signed
original of this written statement required by Section 906 has been provided to
Jinzanghuang Tibet Pharmaceuticals, Inc. and will be retained by Jinzanghuang
Tibet Pharmaceuticals, Inc. and furnished to the Securities and Exchange
Commission or its staff upon request.





May
      17, 2010
            /s/ Xue
      BangyiXue
      Bangyi (Chief Executive Officer)May
      17, 2010
            /s/ Zeng
      YilingZeng
      Yiling (Chief Financial Officer)
```
 
 
CRUDE OIL, LIGHT SWEET - ICE FUTURES EUROPE                          Code-067411
FUTURES ONLY POSITIONS AS OF 04/02/13                         |
--------------------------------------------------------------| NONREPORTABLE
      NON-COMMERCIAL      |   COMMERCIAL    |      TOTAL      |   POSITIONS
--------------------------|-----------------|-----------------|-----------------
  LONG  | SHORT  |SPREADS |  LONG  | SHORT  |  LONG  | SHORT  |  LONG  | SHORT
--------------------------------------------------------------------------------
(CONTRACTS OF 1,000 BARRELS)                         OPEN INTEREST:      535,648
COMMITMENTS
  97,395   35,061  135,524  283,005  347,779  515,924  518,364   19,724   17,284

CHANGES FROM 03/26/13 (CHANGE IN OPEN INTEREST:     15,647)
   2,128    2,008   -1,799   15,278   17,071   15,607   17,280       40   -1,633

PERCENT OF OPEN INTEREST FOR EACH CATEGORY OF TRADERS
    18.2      6.5     25.3     52.8     64.9     96.3     96.8      3.7      3.2

NUMBER OF TRADERS IN EACH CATEGORY (TOTAL TRADERS:      157)
      48       37       64       60       66      136      141
```

----

Updated April 5, 2013
[Federal Register Volume 87, Number 103 (Friday, May 27, 2022)]
[Notices]
[Pages 32176-32177]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-11453]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Human Genome Research Institute; Notice of Closed 
Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Center for Inherited Disease Research Access 
Committee.
    Date: July 8, 2022.
    Time: 11:30 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.

[[Page 32177]]

    Place: National Human Genome Research Institute, National 
Institutes of Health, 6700B Rockledge Drive, Suite 300, Bethesda, MD 
20892 (Virtual Meeting).
    Contact Person: Barbara J. Thomas, Ph.D., Scientific Review 
Officer, National Human Genome Research Institute, National 
Institutes of Health, 6700B Rockledge Drive, Suite 300, Bethesda, MD 
20892, 301-402-8837, <a href="/cdn-cgi/l/email-protection#264447544447544708524e494b475566484f4e08414950"><span class="__cf_email__" data-cfemail="75171407171407145b011d1a181406351b1c1d5b121a03">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human 
Genome Research, National Institutes of Health, HHS)

    Dated: May 24, 2022.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-11453 Filed 5-26-22; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Jason Isaiah ROBINSON, petitioner, v. Lorie DAVIS, Director, Texas Department of Criminal Justice, Correctional Institutions Division.

No. 19-883

Supreme Court of the United States.

Feb. 24, 2020

Petition for writ of certiorari to the United States Court of Appeals for the Fifth Circuit denied.
THE THIRTEENTH COURT OF APPEALS

13-17-00112-CR

Eduardo Luna Rodriguez

v.

The State of Texas

On Appeal from the

107th District Court of Cameron County, Texas

Trial Cause No. 2016-DCR-30-A

JUDGMENT

THE THIRTEENTH COURT OF APPEALS, having considered this cause on 

appeal, concludes that the judgment of the trial court should be AFFIRMED. The Court 

orders the judgment of the trial court AFFIRMED.

We further order this decision certified below for observance.

January 24, 2019
```

[Congressional Bills 106th Congress]
[From the U.S. Government Publishing Office]
[H.R. 2134 Introduced in House (IH)]

106th CONGRESS
  1st Session
                                H. R. 2134

     To suspend temporarily the duty on Cibacron Scarlet LS-2G HC.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             June 10, 1999

  Mr. Coble introduced the following bill; which was referred to the 
                      Committee on Ways and Means

_______________________________________________________________________

                                 A BILL

 
     To suspend temporarily the duty on Cibacron Scarlet LS-2G HC.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. TEMPORARY SUSPENSION OF DUTY.

    (a) In General.--Subchapter II of chapter 99 of the Harmonized 
Tariff Schedule of the United States is amended by inserting in 
numerical sequence the following new heading:

``      9902.32.86      2-                  Free         No change        No change        On or before 12/
                         Naphthalenesulfon                                                  31/2003          ''.
                         ic acid. 7,7-[(2-
                         methyl-1,5-
                         pentanediyl)
                         bis[imino(6-
                         fluoro-1,3,5-
                         triazine-4,2-
                         diyl) imino]]
                         bis[4-hydroxy-3-
                         [(4-methoxy
                         sulfophenyl) azo]-
                         , potassium
                         sodium salt (CAS
                         No. 152397-21-2)
                         (provided for in
                         subheading
                         3204.16.30)......

    (b) Effective Date.--The amendment made by subsection (a) shall 
apply with respect to goods entered, or withdrawn from warehouse for 
consumption, on or after the date that is 15 days after the date of the 
enactment of this Act.
                                 <all>
```
**EXHIBIT32**

 

**CERTIFICATIONSPURSUANT TO 18 UNITED STATES CODE § 1350**

 

Each of theundersigned hereby certifies that to his knowledge the quarterly report on Form10-Q for the fiscal period ended March 31, 2007 of Lincoln Benefit Life Companyfiled with the Securities and Exchange Commission fully complies with therequirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934and that the information contained in such report fairly presents, in allmaterial respects, the financial condition and result of operations of LincolnBenefit Life Company.

 

May 7, 2007

 
|   |   | /s/ James E. Hohmann    |   |
|--------|--------|-------------------------|--------|
|   |   | James E. Hohmann        |
|   |   | President and           |
|   |   | Chief Executive Officer |
|   |   |                    |
|   |   | /s/ John C. Pintozzi    |   |
|   |   | John C. Pintozzi        |
|   |   | Vice President and      |
|   |   | Chief Financial Officer |
|        |        |                         |        |  |

 

E-4

----
<TABLE> <S> <C>

<ARTICLE>                     5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED
FROM THE STATEMENTS FOR THE NINE MONTHS ENDED DECEMBER 31, 1997 AND
AS OF DECEMBER 31, 1997 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE
TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<CIK>                    0000911317
<NAME> HERMATON COMPANY
<MULTIPLIER>                    1
<CURRENCY>                      US dollars
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                              Mar-31-1997
<PERIOD-START>                                 Apr-01-1996
<PERIOD-END>                                   Dec-31-1997
<EXCHANGE-RATE>                                1
<CASH>                                         0
<SECURITIES>                                   0
<RECEIVABLES>                                  0
<ALLOWANCES>                                   0
<INVENTORY>                                    0
<CURRENT-ASSETS>                               0
<PP&E>                                         0
<DEPRECIATION>                                 0
<TOTAL-ASSETS>                                 0
<CURRENT-LIABILITIES>                          2,649
<BONDS>                                        0
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       4,446
<OTHER-SE>                                     (7,095)
<TOTAL-LIABILITY-AND-EQUITY>                   0
<SALES>                                        0
<TOTAL-REVENUES>                               0
<CGS>                                          0
<TOTAL-COSTS>                                  59
<OTHER-EXPENSES>                               0
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             0
<INCOME-PRETAX>                                (59)
<INCOME-TAX>                                   0
<INCOME-CONTINUING>                            (59)
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   (59)
<EPS-PRIMARY>                                  (.00)
<EPS-DILUTED>                                  (.00)
        

</TABLE>
John LASCHKEWITSCH, petitioner, v. TRANSAMERICA LIFE INSURANCE COMPANY.

No. 17-9345.

Supreme Court of the United States

Dec. 3, 2018.

Petition for rehearing denied.